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Abstract. Nowadays, the pharmacological therapy for the treatment of Chagas disease is 
based on two old drugs, benznidazole and nifurtimox, which have restricted efficacy against 
the chronic phase of the illness. To overcome the lack of efficacy of the traditional drugs (and 
their considerable toxicity), new molecular targets have been studied as starting points to the 
discovery of new antichagasic compounds. Among them, polyamine transporter TcPAT12 
(also known as TcPOT1.1) represents an interesting macromolecule, since polyamines are 
essential for Trypanosoma cruzi, the parasite that causes the illness, but it cannot synthesize 
them de novo. In this investigation we report the results of a combined ligand- and structure-
based virtual screening for the discovery of new inhibitors of TcPAT12. Initially we filtered out 
ZINC and Drugbank databases with similarity and QSAR models and then we submitted the 
candidates to a validated docking based screening. Four structures were selected and tested 
in T. cruzi epimastigotes proliferation and two of them, Cisapride and [2-
(cyclopentyloxy)phenyl]methanamine showed inhibitory effects. Additionally, we performed 
transport assays which demonstrated that Cisapride interferes with putrescine uptake in a 
specific mode. 
 
Keywords Chagas disease, Drug repositioning, Cisapride, QSAR, Docking, TcPAT12, 
TcPOT1.1. 
 
1. Introduction. 
According to paleoparasitological data, American trypanosomiasis (also known as Chagas 
disease) is an illness as old as the human presence in the Americas [1]. It was first described 
by Carlos Chagas more than a century ago [2] and it remains endemic to twenty one Latin 
America countries [3]. Additionally, population of other regions (such as Canada, United 
States, Western Pacific and Europe countries) recently started suffering from the disease, 
mainly due to migratory movements of infected patients [3]. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Multi-country initiatives and control campaigns supported by international organisms such as 
the World Health Organization have substantially reduced the incidence of American 
trypanosomiasis in the last fifteen years. However, there are still about 7 million people 
worldwide infected with Trypanosoma cruzi, the parasite that causes the disease [3]. 
Regarding the pharmacological treatment, only two trypanocidal drugs are currently used: 
benznidazole and nifurtimox. They are effective in the initial, acute phase of the disease but 
they show limited efficacy against the chronic stage of the infection [4-5]. During such stage 
the parasites are located mainly in the heart and digestive muscles; and patients can suffer 
from serious affections on the heart, digestive system and/or, in particular clinical conditions, 
nervous system [4]. The lack of efficacy of the traditional drugs for the treatment in the chronic 
phase of the disease in adults and their substantial toxicity explain the need of new active 
compounds for the treatment of the disease. Interesting advances have been made in this 
direction, mainly based on the ever growing knowledge of the molecular biology and the 
biochemistry of T. cruzi. 
Numerous molecular targets in the parasite have been studied as possible points of 
intervention with therapeutic objectives. These macromolecules have the common 
characteristic of being determinants for the parasite survival and/or proliferation, but they are 
absent (or at least considerably different) in the mammalian host [6]. Among them, in this 
investigation, we have focused on the polyamine transporter TcPAT12 [7] (also known as 
TcPOT1.1 [8]) as a potential target for the treatment of Chagas disease. This permease, with 
orthologous sequences in other protozoan parasites such as Leishmania spp., Plasmodium 
spp., and Trypanosoma brucei, belongs to the amino acid/auxin family (AAAP family), a group 
of permeases with no homology in the mammalian lineage [9]. Since polyamines are essential 
for cell survival, differentiation, proliferation and infection of T. cruzi [10-11] but it cannot 
synthesize them de novo [12-13], the inhibition of the polyamine uptake prevents the parasite 
cycle progression [14-15], showing the potential of TcPAT12 as a new therapeutic target for 
Chagas disease. 
Here, we report a search strategy for new putative inhibitors of the transporter TcPAT12 by the 
implementation of a virtual screening (VS) campaign. We have selected a sequential approach 
that involves an initial searching with ligand-based filters followed by the application of a 
target-based method to decide the best candidates. As result, we have tested four 
compounds, and two of them showed interesting results in epimastigote proliferation, one of 
them affecting the TcPAT12 activity. 
 
2. Materials and methods 
2.1 Ligand-based methods for VS 
The initial strategy for the selection of candidates was based on the analysis of known 
inhibitors. It is worth mentioning that the number of compounds that interact with TcPAT12 
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reported in literature is scarce. There are few studies about the effect elicited by several small 
structures over polyamine incorporation in T. cruzi cells [16-18]; such information was used for 
the selection of query molecules to be used in molecular similarity-based searches and for the 
construction of the validation set for docking calculations. 
We started the VS campaign with ligand-based similarity filters. FP2 fingerprints and Tanimoto 
coefficient were employed for the quantification of molecular similarities; both were calculated 
by Open Babel 2.3.2 software [19]. Agmatine, Paroxetine, Triclabendazole, Sertaconazole, 
Pentamidine and Carbonyl cyanide m-chlorophenylsydrazone were used as molecular queries. 
The selection of the queries was based on the information compiled from literature. The 
compounds mentioned before display inhibition of the putrescine transport in the micromolar 
range of concentration [16-18]. 
One of the major drawbacks of similarity-based methods is their dependency on the input 
molecules. To overcome this restriction we complemented the similarity-based VS with a 
recently reported ensemble of QSAR classifiers capable of identifying polyamine analogs with 
anti-protozoal activity [18]. 
 
2.2 Protein structure modeling and docking study 
We implemented standard computational strategies to construct tridimensional models of 
TcPAT12, since its experimental structure is not yet available. The transporter sequence was 
taken from Uniprot database [20] (accession code B2CQQ7) and it was employed to find the 
best fitting templates among known 3D structures. By means of Blast server [21] we identified 
the arginine/agmatine antiporter (AdiC) from E. coli (Protein data bank [22] accession code: 
3L1L) as the most suitable template. This experimental structure was also selected as 
template by the other authors who previously proposed 3D models of the transporter [23-24]. 
The final models were constructed using GPCR-I-TASSER server [25] and Modeller software 
[26-28]. Among the models achieved for the target, we selected for docking calculations the 
one with the highest score obtained from Modeller software.  
The selection of the docking protocol for VS was based on their capacity to discriminate known 
inhibitors from non-inhibitors of TcPAT12 through the docking score. For this purpose, we 
collected from literature those compounds that were tested as inhibitors of the polyamine 
transportation by in vitro models [16-18] and we simulated their interaction with the target by 
docking (see Table 1 in Results and Discussion section). The set of active compounds 
included the structures previously employed for similarity search and other two molecules, 2,4-
dinitrophenol and N-Ethylmaleimidine, which evidenced inhibition at millimolar range of 
concentration [16]. The criterion for the inclusion of these two structures was to increase the 
number of active compounds in the test set. 
Autodock 4.2 [29] and Autodock Vina [30] software were evaluated by means of both rigid and 
flexible modes. The “docking active site“ was defined based on previous investigations that 
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proposed the location of the putrescine-binding pocket [23]. It includes Gly69, Cys66, Trp241, 
Ala244, Asn145, Cys396, Asn245, Tyr148, Tyr400 amino acids [23].  
During Autodock4.2 calculations we set the default spacing (0.375 A) in a grid with 44x58x40 
grid points in x, y, z directions. Additionally, we performed the standard estimation for all the 
variables such as Marsilli-Gasteiger partial charges. We computed 100 docking runs for each 
compound, with the rotation of all non-ring torsion angles. In the case of flexible dockings, the 
same parameters and conditions were considered but adding these standard calculations for 
the mobile residues. 
A similar protocol was implemented for Autodock Vina. It has been proposed that this docking 
software has a better performance over Autodock both in speed and accuracy [30]. However, 
we tested both softwares because they have different scoring functions, and their accuracy is 
highly dependent of the ligand-target system under study [31]. In this case we kept a similar 
grid size as for Autodock, and the standard grid spacing. The number of docking runs was set 
to 20 for each compound, allowing the rotation of their non-ring torsion angles. We also 
enabled mobile residues to compare the performance with the rigid model and with Autodock 
runs. The results are given in Results and Discussion section. 
 
2.3 Virtual screening 
The similarity search was conducted on Drugbank 5.0 [32] and Zinc12 [33] databases. 
Drugbank compiles 8,261 compounds, which are mostly experimental drugs (6,000 structures) 
and also contains nutraceuticals (94 compounds) and FDA-approved drugs (2,021 FDA-
approved small drugs and 233 FDA-peptide drugs). To discover TcPAT12 inhibitors from this 
set of structures would lead to a drug repositioned for this new indication, with all the 
advantages that drug repositioning holds regarding the optimization of time and resources 
involved in the process of drug development. Zinc12 database was used to expand the 
number of chemical scaffolds as well as the number of structures for the screening. We 
selected its Druglike subset that comprises 17,900,742 purchasable compounds [33]. As 
mentioned before, the templates for similarity searching were Agmatine, Paroxetine, 
Triclabendazole, Sertaconazole, Pentamidine and Carbonyl cyanide m-
chlorophenylhydrazone. The screening was performed using Open Babel 2.3.2 software. We 
set a similarity threshold value of 0.5 for Drugbank. In case of ZINC a more demanding filter 
was established (threshold value 0.7) due to the bigger size of the database. 
A parallel ligand-based search was performed with the 6-QSAR model ensemble [18]. We 
employed an ensemble of the six best previously reported individual models, using the 
minimum operator to obtain the final score. Such ensemble was applied in the VS using a 
score of -0.1457 as the threshold value to discern inhibitors from non-inhibitors. Further 
information can be found in the original report [18]. 
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The resulting hits were submitted to the structure-based VS step, using the TcPAT12 
homology model described in section 2.2. An illustration of the VS screening protocol can be 
visualized in Figure 1. 
Figure 1. Schematic illustration of the VS protocol used in this investigation. 
 
2.4 Biological Assays 
2.4.a- Inhibitory effects on T. cruzi epimastigote proliferation. Epimastigotes of the T. cruzi 
strain Y were cultured at 28°C with slightly shaking in BHT medium supplemented with 20 
mg/L hemin (Sigma), 10% (v/v) heat-inactivated fetal calf serum (Natocor) and antibiotics (100 
µg/mL streptomycin and 100 U/mL penicillin) [18] adding each one of the selected candidate 
compounds at 0 – 200 µM on 0.1% DMSO. The tested candidate compounds were Cisapride 
(a gastroprokinetic agent) from Saporiti, and three purchasable amines: ±1-(2,6-
Dimethylphenoxy)-2-propanamide (also known as Mexiletine, Compound 1) from Sigma 
Aldrich), and 4-(3-(1,3-benzodoxol-5-yloxy) propyl-methyl-amino) cyclohexyl) methanol 
(Compound 2) and [2-(cyclopentyloxy)phenyl]methanamine (Compound 3) from Enamine. 
Benznidazole (Sigma Aldrich) was used as a reference proliferation inhibitor. 
Cultures were initiated at 106 cells/mL, and proliferation was followed by periodically cell 
counting in a hemocytometer chamber. In order to compare the effect of each treatment, at 
least three independent experiment were used to determine the parameters maximum cell 
density at seventh day of culture, and IC50 (concentration that inhibited 50% of parasite 
proliferation), evaluated by regression analysis of the data with GraphPad Prism 5 Software. 
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2.4.b- Compounds effect on putrescine uptake. The inhibitory effect of the selected 
compounds on putrescine uptake was determined as previously reported [18]. Briefly: Aliquots 
of T. cruzi epimastigotes (3x107 parasites) grown for 6 h in a polyamine depleted medium were 
centrifuged at 1500g for 4 min and washed three times with phosphate-buffered saline (PBS). 
The cells were then resuspended in 2 mL of PBS containing 5 µM [14C]-putrescine and the 
selected compounds, or putrescine as isotopic displacement control, at a final concentration of 
50 µM on 0.1% DMSO. To stop the reaction, aliquots were taken at the indicated times and 
washed twice by centrifugation with 1 mL of ice-cold PBS and 10 mM putrescine, for isotopic 
dilution. Pellets were resuspended and radioactivity determined in UltimaGold XR. Similar 
procedure was followed using 5 µM [1,4-14C ]-arginine instead of [14C]-putrescine, in order to 
check the specificity of compounds effect on putrescine uptake [34]. 
Possible toxic effects of candidate compounds on the epimastigotes under uptake assay 
conditions were discarded by the 3-(4,5-dimethyl-thiazol-2-yl)-2,5-di-phenyltetrazolium bromide 
(MTT) assay (Sigma Aldrich), following the supplier's instructions. In this assay it is determined 
the capacity of the cell to convert MTT to an acidic isopropanol-soluble blue formazan 
derivative detected by absorbance at 570 nm. 
All assays were made in duplicate and statistical analysis was performed in GraphPad Prism 5 
Software. Groups were analyzed using one-way ANOVA test followed by a post-hoc Dunnett's 
multiple comparison test (significance cut-off value p= 0.05). 
 
3. Results and Discussion 
 
3.1 Virtual screening 
The ligand-based VS of the databases identified 594 candidates, which were selected for the 
target-based VS. These compounds showed either similarity with some of the queries used in 
the similarity-based VS or were classified as active by the QSAR model-ensemble. 
The best model of TcPAT12 architecture was achieved by Modeller Software (Figure 2A), 
which employed the 3D structure of arginine/agmatine antiporter (AdiC) from E. coli as 
template. These results are in concordance with previous predictions of the structure of the 
transporter, which were based on the same template [23-24]. It was identified through Blast 
sequence search from Chimera software [35]. AdiC showed 23% of sequence identity and 
64% coverage of the entire query sequence. The model is composed by 12 transmembrane 
domains with a region of helical discontinuity. The model includes the sequence portion 
between amino acids 45 and 514 and contains the putrescine-binding pocket (that is, the 
region needed for docking calculations). The residues uncovered belong to the C- and N-
terminus of the transporter. Figure 2B shows a comparison between the putative ligand 
binding site of the transporter and the crystal structure of the AdiC arginine binding pocket. 
The architecture of the proposed binding site is similar to the one previously suggested by 
Hasne and coworkers [23]. As these authors explained before, the α-amino group of arginine 
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interacts through hydrogen bonds with Ile23, Trp202 and Ile205 in AdiC and these residues 
are Cys66, Trp241 and Ala244 in the parasite transporter (Figure 2B1). The structural 
differences between the natural ligands (arginine for AdiC and polyamines for TcPAT12) 
explain the dissimilarities found in the nature of the residues of the binding sites. For example, 
the carboxylate group of arginine promotes a hydrogen bonding interaction with the hydroxyl 
group of Ser26 in the prokaryotic antiporter, whereas this position is occupied by Gly69 in the 
model of the polyamine transporter (Figure 2B2) [23]. Additionally, the interaction of the 
guanidine function of arginine with Asn101 and Ser357 in AdiC is partially lost in TcPAT12 
model, where the residues are replaced by Asn145 and Cys396 respectively [23]. We also 
found important residues proposed by Hasne as places of interaction with the polyamine 
ligands, which are not conserved in AdiC. They are Asn245, Tyr148 and Tyr400 (Figure 2B1) 
[23].  
Ramachandran plot obtained from the model (Figure A1 in Supporting Information section) 
shows that the backbone dihedral angles are mainly distributed in allowed regions (96%), and 
none of the residues located in non-allowed regions were involved in the active site of the 
transporter. Even it is known that the structural characteristics of membrane proteins (such as 
atomic interactions and solvation properties) do not follow the same distribution as proteins in 
solution [36], the quality of the model was also estimated with the normalized Discrete 
Optimized Protein Energy parameter (z-DOPE) and the GA341 score (which analyze the 
reliability of a model based on statistical potentials) [37]. The values were 0.8 for z-DOPE and 
0.723 for GA341. These results showed that the model has an acceptable reliability (given by 
GA341 values higher than 0,7) but the z-DOPE score is higher than expected (negative values 
indicate better models). The z-DOPE value was calculated based on native structures of 
macromolecules and may be biased towards globular proteins that may not follow the same 
distribution values for structural properties as those from membrane proteins. Therefore we 
decided to use the model for virtual screening based on the Ramachandran plot results and 
the fact that it is able to reproduce the position and orientation of key residues of the binding 
site mentioned previously in the text [23].  
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Figure 2. The three-dimensional model of TcPAT12 architecture used for virtual screening. A: 
side view of the model. B: Superposition of the putative binding site of the model (in green) 
and AdiC binding pocket (in cyan). Important residues of TcPAT12 model are highlighted as 
sticks with the following color code: carbon atoms in green, oxygen atoms in red, nitrogen 
atoms in blue and sulfur atoms in yellow. The corresponding amino acids of AdiC were 
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highlighted as cyan sticks. Arginine ligand of AdiC has carbon atoms in yellow. B1: residues 
predicted to be involved in polyamine recognition B2: Important residues that interacts with 
carboxylic and guanidine function of the ligand in AdiC and the corresponding residues in 
TcPAT12. 
 
The docking protocol for VS was selected by considering the capacity of the docking software 
to identify known active compounds. As mentioned before, the information available in 
literature refers to several small molecules that interfere (or not) in the process of polyamines 
uptake in T. cruzi cells. Table 1 shows the scores achieved by the simulation of the interaction 
of these molecules with the target, through the execution of different docking protocols. 2,4-
dinitrophenol, Agmatine, Paroxetine, Carbonyl cyanide m-chlorophenylhydrazone, 
Triclabendazole, N-Ethylmaleimidine, Sertaconazole, and Pentamidine were reported as 
inhibitors of the polyamine transport whereas Spermine and the amino acids Aspartate, 
Asparagine, Lysine and Serine were considered non-inhibitors [16-18]. The natural ligands of 
the transporter (cadaverine and putrescine) were also included within the validation set. 
For Autodock 4.2 we considered TcPAT12 as a rigid structure in the first model (M1, Table 1). 
Additionally three different set of amino acids of the active site were allowed to move in the 
Autodock flexible docking simulations (M2 to M4, Table 1). The criterion of selection of the 
mobile residues was based on the analysis of the amino acids that interact with the natural 
ligands (cadaverine and putrescine) in the rigid simulations. We found hydrogen bonding 
interactions between the ligands and Glu247 (Figure A2 in Supporting Information section). 
Additionally, Tyr148 pointed its hydroxyl group to one amino moiety of the ligands, so both 
aminoacids were considered flexible in order to optimize these of interactions (M2). Asn145 
was also included as flexible with the same criteria (M4). Finally Trp241 and Ala244 side 
chains were allowed to move in order to analyze the effect of possible hydrophobic interactions 
(M3). Similarly, we performed docking calculations with Autodock Vina software (models M5 to 
M8, Table 1). 
Autodock Vina simulations calculated lower scores for the inhibitors than reference ligands 
showing their ability to identify them as active compounds. Models M6, M7 and M8 recognized 
100% of the inhibitors with a lower score than putrescine and cadaverine.  However, these 
simulations assigned also lower scores to non-inhibitors and they were able to identify only 
one non inhibitor through the docking score.  
 
 
Table 1. Docking scores for the test set. Flexible residues are included between brackets. 
Inactive compounds are shown in italic. Amino acids were docked in their L and D 
configurations, only the best docking score is reported in the table. Reference ligands are 
shown in bold. 
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The models based on Autodock4.2 simulations showed an acceptable ability to identify 
inhibitors. M1 and M3 were able to detect most of the inhibitors through their score (75% of 
them, in relation to the reference ligands). Additionally, M1 showed about 70% of non-
inhibitors correctly classified. This specificity in the validation set is important to reduce the 
selection of false positives in VS, even at expenses of losing some true positives during the 
search (M1 displays a sensibility rate lower than Autodock Vina models). We also tested the 
docking conditions recently reported by Reigada and coworkers for VS [24]. The authors 
considered Asn245, Tyr148 and Tyr400 as flexible residues and performed the simulations 
using Autodock4.2 software. We applied this model to our test set (M9) and a similar protocol 
 
 
 
Compound 
M1 
(rigid) 
M 2 
(Glu247 
Tyr148) 
M 3 
(Glu247 
Tyr148 
Trp241 
Ala244) 
M 4 
(Glu247 
Tyr148 
Asn245) 
M 5 
(rigid) 
 
M 6 
(Glu247  
Tyr148) 
M7 
(Glu247 
Tyr148 
Trp241 
Ala244) 
M8 
(Glu247 
Tyr148 
Asn245) 
2,4-dinitrophenol -5.5 -10.3 -13.3 -9.6 -7.0 -7.6 -7.2 -6.9 
Agmatine -6.6 -13.5 -15.1 -12.1 -5.2 -5.7 -5.6 -5.7 
Paroxetine -9.0 -16.0 -17.6 -14.6 -4.3 -7.9 -7.9 -8.0 
Carbonyl cyanide m-
chlorophenylhydraz
one 
-7.1 -12.2 -14.3 -10.7 -7.1 -7.3 -7.7 -7.3 
Triclabendazole -8.1 -13.1 -15.4 -11.4 -3.5 -5.5 -7.4 -5.2 
N-Ethylmaleimidine -4.8 -10.0 -11.7 -8.2 -5.2 -5.3 -5.4 -5.4 
Sertaconazole -9.4 -15.8 -17.3 -15.7 -3.3 -5.8 -7.6 -5.7 
Pentamidine -9.3 -15.1 -17.6 -12.8 -5.5 -7.9 -8.6 -8.1 
Cadaverine -5.9 -12.6 -14.2 -10.8 -4.1 -4.6 -4.6 -4.6 
Putrescine -6.0 -11.7 -13.3 -10.3 -3.8 -4.4 -4.4 -4.4 
Spermine -7.1 -14.1 -15.0 -12.6 -5.4 -5.9 -6.0 -5.9 
Aspartate -5.5 -10.4 -13.0 -8.7 -5.1 -5.2 -5.2 -5.2 
Asparagine -5.7 -12.1 -14.7 -9.6 -5.3 -5.4 -5.6 -5.4 
Leucine -5.8 -11.3 -13.6 -9.8 -5.3 -5.2 -5.2 -5.2 
Lysine -8.0 -14.2 -16.4 -12.6 -5.0 -5.6 -5.7 -5.7 
Serine -5.5 -11.8 -13.9 -10.1 -4.4 -4.3 -4.3 -4.2 
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with Autodock Vina software (M10). The results evidence lower performances than M1 in 
terms of specificity. Table S1 shows the results achieved from M9 and M10 and Table S2 
shows the percentage of false-positives, false-negatives, true-positives and true-negatives for 
all simulations.  
As an additional validation of the M1 model, we tested its capacity to reproduce the 
experimental binding mode of the complex between Arginine and the Arginine/Agmatine 
antiporter (AdiC) from E. coli, the template selected for the construction of the TcPAT12. The 
results are shown in Figure 3.  
 
 
 
 
 
Figure 3. Superposition of the docking conformation (in magenta) and the crystallographic 
ligand (in light blue) in the active site of AdiC (PDB code 3L1L). Hydrogen atoms were omitted 
for simplicity. 
 
The results previously mentioned, based on the information of true inhibitors and no inhibitors, 
allowed us to select M1 as the best docking protocol for the target-based conducting the VS. 
The performance of M1 in a VS context was analyzed by constructing a ”simulated database” 
that contains a set of presumed active compounds dispersed in a large number of apparent  
inactive structures. To this end, we defined as active putrescine, cadaverine and the inhibitors 
collected from literature as active (Table 1). Additionally, we increased the number of putative 
inhibitors through the inclusion of the 25 polyamide analogs with activity towards T. Cruzi 
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found in literature [18]. These polyamide analogs were previously considered as active for the 
construction of the QSAR model included in this investigation [18]. On the other hand, we 
judge as inactive the noninhibitors of the test set (Table 1) and 411 decoys generated with the 
Enhanced Directory of Useful Decoys resource (DUD-E) [38]. The decoys were calculated 
from the smiles codes of the active molecules used for similarity searching (Agmatine, 
Paroxetine, Triclabendazole, Sertaconazole, Pentamidine and Carbonyl cyanide m-
chlorophenylsydrazone) plus putrescine and cadaverine. The performance of M1 over the 
simulated database was tested through the area under the Receiving Operating Characteristic 
(ROC) curve. It plots the sensibility of the model (true positive rate) as a function of the false 
positive rate (1−specificity) at predefined threshold settings [39]. The area under the curve 
(AUC) will be equal to 1 in an ideal performance while an AUC of 0.5 will represent a random 
selection of active and inactive compounds through the docking scores. The AUC value 
calculated for M1 was 0.71, which represents a moderate predictive capacity. To the extent of 
our knowledge previous docking based virtual screening campaigns against TcPAT12 did not 
report this metric, so we cannot compare our AUC value with the one obtained from other 
researchers. Finally we measured the enrichment of inhibitors among the top-ranking scores of 
the simulated database through the enrichment factor (EF) [40]. We found an EF value of 4 for 
the first 10% of the database. The metrics exposed the moderate performance of the model, 
and future investigations will be carried out to improve it as new active compounds are 
identified by us as well as by other authors.   
According to the docking scores achieved in the simulated database, we set a cutoff value 
−7.7 Kcal/mol to differentiate active from inactive compounds in the “real“ VS. This value was 
chosen to balance specificity (70%) and sensibility (61%), according to the ROC curve. 
From the 594 structures selected from the ligand-based filters, the target-based VS proposed 
203 candidates that pass the threshold value. The 59 compounds that comprise the top 10% 
of the scores were analyzed. Finally, based on their chemical diversity and accessibility, four of 
them, Cisapride (a gastroprokinetic agent), and three purchasable amines: ±1-(2,6-
Dimethylphenoxy)-2-propanamide (Compound 1), 4-(3-(1,3-benzodoxol-5-yloxy) propyl-
methyl-amino) cyclohexyl) methanol (Compound 2) and [2-
(cyclopentyloxy)phenyl]methanamine (Compound 3) were purchased and tested through in 
vitro assays of T. cruzi epimastigote proliferation and polyamine transport (Figure 4).  
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Figure 4. Candidates acquired for biological testing. 
 
3.2 Biological Assays 
3.2.a- Inhibitory effects on T. cruzi epimastigote proliferation 
The four selected compounds were tested in proliferation assays on epimastigotes, the 
proliferative and non-infective stage of T. cruzi. Curves without compound addition and with 
benznidazole were also done as controls. This in vitro assay is a first approach to evaluate the 
possible effect of a compound as trypanocidal or trypanostatic drug. 
Comparing with control growth curves, compounds 1 and 2 did not exhibit inhibitory activity, 
even at high concentration (200 µM), while 60 µM Cisapride and 100 µM Compound 3 
diminished significantly the maximum cell density (p< 0.05) in the first round of culture (Figure 
5A, B and E), showing IC50 values of 39.7 µM and 41.1 µM respectively. The Cisapride effect 
was observed in a concentration range of 30 – 60 µM; at lower (up to 20 µM) and higher 
concentrations (from 100 µM) the effect progressively disappeared. There are multiple 
possible explanations to such loss of effect at high concentrations, including Cisapride forming 
micelles or precipitating in the culture medium. We have found no evidences in the literature 
on Cisapride forming micelles (aside, its molecular structure does not resemble a surfactant to 
exhibit such behavior).  We did not observe precipitation of the compound in culture medium 
up to 400 µM,either. Accordingly, we hypothesize that the observed loss of effect at 
concentrations similar to 100 µM could be a result of induced efflux or elimination, activated 
once that the compound concentration overcomes certain level. 
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Figure 5. Evaluation of candidate compounds in in vitro epimastigotes proliferation assay. To 
follow growth curves and determine maximum cell density at each condition, epimastigotes, 
strain Y, were seeded at 106 cells/ml in BHT medium and maintained at 28 C°. Parasites were 
counted periodically using a hemocytometer chamber. Control condition (0 µM) was tested at 
0.1% DMSO. A) Growth curves of epimastigotes treated with Cisapride or Benznidazole at 
different concentrations, illustrating maximum cell density values obtained at the 7th day of 
culture. One of three independent experiments with similar results is shown. B – E) Effect of 
candidate compounds on maximum cell density reached at the 7th day (first round of culture). 
Cisapride (B), Compound 1 (C), Compound 2 (D), Compound 3 (E). Values are expressed as 
mean ± SD. Statistical analysis was performed by one way ANOVA test followed by a post-hoc 
Dunnett’s multiple comparison test, considering 0 µM as control mean (*p < 0.05, **p < 0.01, 
***p < 0.005). 
 
3.2.- Compounds effect on putrescine uptake 
In order to check if the candidate compounds interfere with putrescine uptake, as predicted by 
our models, we evaluated their competition capacity in a [14C]-putrescine transport assay in T. 
cruzi epimastigotes. The maximal uptake interference was obtained by an isotopic 
displacement control done with non-radioactive 50-fold molar putrescine (not shown). 
Cisapride, at 10-fold molar excess, showed a clear effect on putrescine uptake with a 
significant initial velocity reduction to 53 ± 5.2% (Figure 6A), compared with transport in control 
conditions. In contrast, putrescine uptake was not affected by Compounds 1, 2 and 3 (Figure 
6A). 
The specificity of the inhibitory effect caused by Cisapride on putrescine uptake was checked 
by two different kinds of experiments: by competition assays on Arginine transport, whose 
permease TcAAAP411 belongs to the same family of TcPAT12, the AAAP family [9,34], and 
by evaluation of possible toxicity effect under transport conditions. 
There was no effect of Cisapride on Arginine uptake (Figure 6A, inset – maximal displacement 
effect showed by non-radioactive arginine, not shown) indicating that the observed effect on 
putrescine transport was specific rather than an unspecific effect on AAAP members. 
Complementarily, Compound 3 also was tested for competition on Arginine uptake, confirming 
that its negative effect on epimastigote proliferation was not related with the uptake of 
putrescine nor arginine. On the other hand, it was performed a MTT assay under conditions 
and times of the uptake assay allowing us to discard that the observed effect on putrescine 
uptake with Cisapride was due to compound cytotoxicity (Figure 6B). These results indicate 
that the Cisapride effect was specific on putrescine uptake. 
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Figure 6. Effect of Cisapride and compounds 1, 2 and 3 on putrescine uptake in T. cruzi 
epimastigotes. A- Competition Assay: early log parasite cultures were harvested for 6 hs in a 
polyamine free medium. Then putrescine uptake was assayed at 5 µM [14C]-putrescine and 
initial velocities were calculated at 0.1% DMSO (control condition) and adding 250 µM non-
radioactive putrescine (maximal interference – not shown) or 50 µM of each candidate 
compound. Values are expressed as % mean ± SD with in comparison with control. Statistical 
analysis was performed by one way ANOVA test followed by a post-hoc Dunnett’s multiple 
comparison test (***p < 0.005). Inset: competition assays on Arginine uptake were realized 
with same cultures and conditions with 5 µM [1,4-14C]-Arginine in order to check the specificity 
of compounds effect. B- Viability assay: the metabolic state of the epimastigote cells was 
evaluated by the MTT assay, where tetrazolium salt is reduced to a alcohol-soluble blue 
formazan product determined by Absorbance at 570nm. 
 
 
4 Conclusions 
We have performed a cascade VS campaign by combining parallel similarity and QSAR 
ligand-based VS with subsequent target-based screening of the resulting hits.  
Four of the hits selected in silico were acquired and screened both in T. cruzi epimastigotes 
proliferation and putrescine uptake assays. Two of the assayed hits, Cisapride and 2-
(cyclopentyloxy)phenyl]methanamine (Compound 3), displayed inhibitory effects on 
epimastigote proliferation. In the case of Cisapride, it was verified that this drug interferes with 
putrescine uptake in a specific manner (without impairing arginine uptake or cell viability), 
while no effect on putrescine uptake was observed for Compound 3. The verified effect of 
Cisapride on putrescine uptake confirms the ability of our cascade in silico screen to select 
compounds targeting polyamine uptake. 
It should be underlined that the trypanocidal effects of Cisapride seem to be lost at high 
concentrations, which may be explained through an induced efflux. Future studies should 
assess if such loss at high concentrations is also observed in T. cruzi clinically relevant forms 
(trypomastigotes and amastigotes), in order to evaluate the potential of Cisapride as starting 
point for the development of new medications against Chagas disease. 
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A combined virtual screening was conducted for the discovery of TcPAT12 inhibitors. 
A 3D model of the target was constructed for the target based virtual screening.  
Transport assays showed that Cisapride interferes with putrescine uptake. 
